Roger Chou, MD; Tracy Dana, MLS; Ian Blazina, MPH; Monica Daeges, BA; Christina Bougatsos, MPH; Thomas L. Jeanne, MD, MPH
Disclaimer: The investigators are solely responsible for the content and the decision to submit the manuscript for publication. The views expressed here do not represent and should not be construed to represent a determination or policy of the AHRQ or the U.S. Department of Health and Human Services.
Disclosures: The authors report a contract with the AHRQ during the conduct of the study. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-0946.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer and Johnson & Johnson.
Reproducible Research Statement: Study protocol: Available at www.uspreventiveservicestaskforce.org/Page/Document/final-research-plan98/statin-use-in-adults-preventive-medication1. Statistical code: Not applicable. Data set: Full report available at www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryDraft/statin-use-in-adults-preventive-medication1?ds=1&s=statin.
Requests for Single Reprints: Roger Chou, MD, Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, 3181 Southwest Sam Jackson Park Road, Mail Code: BICC, Portland, OR 97239; e-mail, email@example.com.
Current Author Addresses: Dr. Chou, Ms. Dana, Mr. Blazina, and Ms. Bougatsos: Pacific Northwest Evidence-Based Practice Center, Oregon Health & Science University, 3181 Southwest Sam Jackson Park Road, Mail Code: BICC, Portland, OR 97239.
Ms. Daeges: 1505 Duke University Road, Unit 7D, Durham, NC 27701.
Dr. Jeanne: 2841 Southeast Tibbetts Street, Apartment B, Portland, OR 97202.
Author Contributions: Conception and design: R. Chou, T.L. Jeanne.
Analysis and interpretation of the data: R. Chou, T. Dana, I. Blazina, C. Bougatsos, T.L. Jeanne.
Drafting of the article: R. Chou, C. Bougatsos, T.L. Jeanne.
Critical revision for important intellectual content: R. Chou, I. Blazina.
Final approval of the article: R. Chou, T. Dana, I. Blazina, M. Daeges, C. Bougatsos, T.L. Jeanne.
Provision of study materials or patients: M. Daeges.
Obtaining of funding: R. Chou.
Administrative, technical, or logistic support: T. Dana, I. Blazina, M. Daeges, C. Bougatsos.
Collection and assembly of data: R. Chou, I. Blazina, M. Daeges, C. Bougatsos.
Dyslipidemia may occur in younger adults (defined as persons aged 21 to 39 years) and is an important risk factor for cardiovascular disease. Screening might identify younger adults with asymptomatic dyslipidemia who may benefit from lipid-lowering therapies.
To update the 2008 U.S. Preventive Services Task Force review on dyslipidemia screening in younger adults.
The Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and MEDLINE through May 2016, and reference lists.
Randomized, controlled trials; cohort studies; and case–control studies on screening for or treatment of asymptomatic dyslipidemia in adults aged 21 to 39 years.
The plan was for 1 investigator to abstract data and a second to check their accuracy, and for 2 investigators to independently assess study quality; however, no studies met the inclusion criteria.
No study evaluated the effects of lipid screening versus no screening, treatment versus no treatment, or delayed versus earlier treatment on clinical outcomes in younger adults. In addition, no study evaluated the diagnostic yield of alternative screening strategies (such as targeted screening of persons with a family history of hyperlipidemia vs. general screening) in younger adults.
No direct relevant evidence.
Direct evidence on the benefits and harms of screening for or treatment of dyslipidemia in younger adults remains unavailable. Estimating the potential effects of screening for dyslipidemia in this population requires extrapolation from studies performed in older adults.
Agency for Healthcare Research and Quality.
Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, Jeanne TL. Screening for Dyslipidemia in Younger Adults: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. ;165:560–564. doi: 10.7326/M16-0946
Download citation file:
Published: Ann Intern Med. 2016;165(8):560-564.
Published at www.annals.org on 9 August 2016
Cardiology, Coronary Risk Factors, Dyslipidemia.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use